This study provides a basis for the development and use of selective CSNK1D inhibitors to abrogate HH—GLI signaling in SMOi-sensitive and SMOi-resistant settings, which is an important step towards the development of novel oncology drugs targeting GLI transcription factors to eliminate highly malignant cancer stem cells. This evidence concerns the gene GLI1 and cancer.